Consilium Wealth Advisory’s AbbVie ABBV Stock Holding History

Consilium Wealth Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	6,149 +3,141	+104%	+$676K	0.46%	40
2026 Q1	$654K	Buy	3,008 +1,008	+50%	+$224K	0.22%	66
2025 Q4	$457K	Hold	2,000	–	–	0.17%	70
2025 Q3	$463K	Hold	2,000	–	–	0.18%	72
2025 Q2	$371K	Sell	2,000 -112	-5%	-$20.8K	0.16%	75
2025 Q1	$442K	Sell	2,112 -3,163	-60%	-$615K	0.22%	67
2024 Q4	$937K	Sell	5,275 -2,126	-29%	-$391K	0.45%	41
2024 Q3	$1.46M	Buy	7,401 +5,401	+270%	+$1.01M	0.8%	27
2024 Q2	$343K	Hold	2,000	–	–	0.19%	66
2024 Q1	$364K	Sell	2,000 -1,261	-39%	-$217K	0.2%	66
2023 Q4	$505K	Sell	3,261 -4,209	-56%	-$614K	0.3%	57
2023 Q3	$1.11M	Buy	7,470 +2,854	+62%	+$419K	0.78%	27
2023 Q2	$622K	Buy	4,616 +1,174	+34%	+$172K	0.43%	47
2023 Q1	$549K	Sell	3,442 -377	-10%	-$57.6K	0.47%	45
2022 Q4	$617K	Buy	3,819 +498	+15%	+$76.4K	0.53%	44
2022 Q3	$446K	Buy	3,321 +1,315	+66%	+$189K	0.5%	48
2022 Q2	$307K	Sell	2,006 -220	-10%	-$33.6K	0.33%	61
2022 Q1	$361K	Buy	2,226 +226	+11%	+$32.8K	0.26%	65
2021 Q4	$271K	Buy	+2,000	New	+$236K	0.18%	78

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Consilium Wealth Advisory's ABBV Position: Q2 2026 in Review

Consilium Wealth Advisory increased its AbbVie (ABBV) stake by 104% in Q2 2026, buying an estimated $676K and bringing the position to 6,149 shares worth $1.55M. The position accounts for 0.46% of the portfolio, ranked #40.

Consilium Wealth Advisory first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Consilium Wealth Advisory held 6,149 shares of AbbVie worth $1.55M as of Q2 2026.
Consilium Wealth Advisory bought 3,141 AbbVie shares in Q2 2026, an estimated $676K.
AbbVie made up 0.46% of Consilium Wealth Advisory's portfolio in Q2 2026, its #40 holding.
Consilium Wealth Advisory first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Consilium Wealth Advisory's 13F filing for Q2 2026, filed 11 Aug 2026.